Andrew J Mcmichael

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6750811/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	An immunodominant NP105–113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease. Nature Immunology, 2022, 23, 50-61.	14.5	110
2	Mouse and human antibodies bind HLA-E-leader peptide complexes and enhance NK cell cytotoxicity. Communications Biology, 2022, 5, 271.	4.4	14
3	GIMAP6 regulates autophagy, immune competence, and inflammation in mice and humans. Journal of Experimental Medicine, 2022, 219, .	8.5	4
4	Primary and secondary functions of HLA-E are determined by stability and conformation of the peptide-bound complexes. Cell Reports, 2022, 39, 110959.	6.4	8
5	HLA-E–restricted, Gag-specific CD8 ⁺ T cells can suppress HIV-1 infection, offering vaccine opportunities. Science Immunology, 2021, 6, .	11.9	35
6	The Importance of Cellular Immune Response to HIV: Implications for Antibody Production and Vaccine Design. DNA and Cell Biology, 2021, , .	1.9	3
7	Preexisting memory CD4+ T cells contribute to the primary response in an HIV-1 vaccine trial. Journal of Clinical Investigation, 2021, 131, .	8.2	6
8	CD4+ T Follicular Helper Cells in Human Tonsils and Blood Are Clonally Convergent but Divergent from Non-Tfh CD4+ Cells. Cell Reports, 2020, 30, 137-152.e5.	6.4	74
9	Detailed and atypical HLAâ€E peptide binding motifs revealed by a novel peptide exchange binding assay. European Journal of Immunology, 2020, 50, 2075-2091.	2.9	24
10	Interrogating the recognition landscape of a conserved HIV-specific TCR reveals distinct bacterial peptide cross-reactivity. ELife, 2020, 9, .	6.0	6
11	Capturing the antigen landscape: HLA-E, CD1 and MR1. Current Opinion in Immunology, 2019, 59, 121-129.	5.5	17
12	Topological perspective on HIV escape. Science, 2019, 364, 438-439.	12.6	4
13	Casting a wider net: Immunosurveillance by nonclassical MHC molecules. PLoS Pathogens, 2019, 15, e1007567.	4.7	49
14	Contribution of proteasome-catalyzed peptide <i>cis</i> -splicing to viral targeting by CD8 ⁺ T cells in HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 24748-24759.	7.1	48
15	Lack of Truncated IFITM3 Transcripts in Cells Homozygous for the rs12252-C Variant That is Associated With Severe Influenza Infection. Journal of Infectious Diseases, 2018, 217, 257-262.	4.0	40
16	Is a Human CD8 T-Cell Vaccine Possible, and if So, What Would It Take?. Cold Spring Harbor Perspectives in Biology, 2018, 10, a029124.	5.5	12
17	The Role of MHC-E in T Cell Immunity Is Conserved among Humans, Rhesus Macaques, and Cynomolgus Macaques. Journal of Immunology, 2018, 200, 49-60.	0.8	54
18	Brigitte Alice Askonas. 1 April 1923—9 January 2013. Biographical Memoirs of Fellows of the Royal Society, 2018, 65, 31-45.	0.1	0

#	Article	IF	CITATIONS
19	Legacy of the influenza pandemic 1918: The host TÂcell response. Biomedical Journal, 2018, 41, 242-248.	3.1	6
20	Identification of novel HIV-1-derived HLA-E-binding peptides. Immunology Letters, 2018, 202, 65-72.	2.5	21
21	Tracking HIV-1 recombination to resolve its contribution to HIV-1 evolution in natural infection. Nature Communications, 2018, 9, 1928.	12.8	83
22	Antisense-Derived HIV-1 Cryptic Epitopes Are Not Major Drivers of Viral Evolution during the Acute Phase of Infection. Journal of Virology, 2018, 92, .	3.4	3
23	Pathogen-derived HLA-E bound epitopes reveal broad primary anchor pocket tolerability and conformationally malleable peptide binding. Nature Communications, 2018, 9, 3137.	12.8	57
24	HIV-1 Conserved Mosaics Delivered by Regimens with Integration-Deficient DC-Targeting Lentiviral Vector Induce Robust T Cells. Molecular Therapy, 2017, 25, 494-503.	8.2	19
25	Unusual antigen presentation offers new insight into HIV vaccine design. Current Opinion in Immunology, 2017, 46, 75-81.	5.5	12
26	A strongly selected mutation in the HIV-1 genome is independent of T cell responses and neutralizing antibodies. Retrovirology, 2017, 14, 46.	2.0	2
27	M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza. JCI Insight, 2017, 2, e91868.	5.0	59
28	Gut microbiota induce local and systemic CD4 T cell responses in healthy individuals that are altered in inflammatory bowel diseases. Zeitschrift Fur Gastroenterologie, 2017, 55, .	0.5	0
29	Relative rate and location of intra-host HIV evolution to evade cellular immunity are predictable. Nature Communications, 2016, 7, 11660.	12.8	103
30	Immune perturbations in HIV-1–infected individuals who make broadly neutralizing antibodies. Science Immunology, 2016, 1, aag0851.	11.9	120
31	Broadly targeted CD8 ⁺ T cell responses restricted by major histocompatibility complex E. Science, 2016, 351, 714-720.	12.6	260
32	Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection. Molecular Therapy, 2016, 24, 832-842.	8.2	107
33	HIV-Host Interactions: Implications for Vaccine Design. Cell Host and Microbe, 2016, 19, 292-303.	11.0	143
34	Temporal Dynamics of CD8+ T Cell Effector Responses during Primary HIV Infection. PLoS Pathogens, 2016, 12, e1005805.	4.7	36
35	Proof-of-Principle for Immune Control of Global HIV-1 Reactivation In Vivo. Clinical Infectious Diseases, 2015, 61, 120-128.	5.8	17
36	Natural T Cell–mediated Protection against Seasonal and Pandemic Influenza. Results of the Flu Watch Cohort Study. American Journal of Respiratory and Critical Care Medicine, 2015, 191, 1422-1431.	5.6	229

#	Article	IF	CITATIONS
37	Reversion and T Cell Escape Mutations Compensate the Fitness Loss of a CD8+ T Cell Escape Mutant in Their Cognate Transmitted/Founder Virus. PLoS ONE, 2014, 9, e102734.	2.5	8
38	Preexisting compensatory amino acids compromise fitness costs of a HIV-1ÂT cell escape mutation. Retrovirology, 2014, 11, 101.	2.0	12
39	Vaccine-elicited Human T Cells Recognizing Conserved Protein Regions Inhibit HIV-1. Molecular Therapy, 2014, 22, 464-475.	8.2	188
40	Vaccines that stimulate T cell immunity to HIV-1: the next step. Nature Immunology, 2014, 15, 319-322.	14.5	72
41	Proteome-wide analysis of HIV-specific naive and memory CD4+ T cells in unexposed blood donors. Journal of Experimental Medicine, 2014, 211, 1273-1280.	8.5	76
42	Ita Askonas and her influence in the field of antigen presentation. Current Opinion in Immunology, 2014, 26, 111-114.	5.5	1
43	Comparison of Neutralizing Antibody Responses Elicited from Highly Diverse Polyvalent Heterotrimeric HIV-1 gp140 Cocktail Immunogens versus a Monovalent Counterpart in Rhesus Macaques. PLoS ONE, 2014, 9, e114709.	2.5	11
44	Influenza vaccines: mTOR inhibition surprisingly leads to protection. Nature Immunology, 2013, 14, 1205-1207.	14.5	5
45	HIV-1 Vaccines: Let's Get Physical. Immunity, 2013, 38, 410-413.	14.3	1
46	High Levels of Virus-Specific CD4 ⁺ T Cells Predict Severe Pandemic Influenza A Virus Infection. American Journal of Respiratory and Critical Care Medicine, 2012, 186, 1292-1297.	5.6	64
47	The T-Cell Response to HIV. Cold Spring Harbor Perspectives in Medicine, 2012, 2, a007054-a007054.	6.2	155
48	Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nature Medicine, 2012, 18, 274-280.	30.7	882
49	Prime-boost regimens with adjuvanted synthetic long peptides elicit T cells and antibodies to conserved regions of HIV-1 in macaques. Aids, 2012, 26, 275-284.	2.2	35
50	Lessons learned from HIV-1 vaccine trials: new priorities and directions. Nature Immunology, 2012, 13, 423-427.	14.5	84
51	Differences in HIV-Specific T Cell Responses between HIV-Exposed and -Unexposed HIV-Seronegative Individuals. Journal of Virology, 2011, 85, 3507-3516.	3.4	38
52	An Early HIV Mutation within an HLA-B*57-Restricted T Cell Epitope Abrogates Binding to the Killer Inhibitory Receptor 3DL1. Journal of Virology, 2011, 85, 5415-5422.	3.4	57
53	Fitness Costs and Diversity of the Cytotoxic T Lymphocyte (CTL) Response Determine the Rate of CTL Escape during Acute and Chronic Phases of HIV Infection. Journal of Virology, 2011, 85, 10518-10528.	3.4	141
54	Protective Efficacy of Serially Up-Ranked Subdominant CD8+ T Cell Epitopes against Virus Challenges. PLoS Pathogens, 2011, 7, e1002041.	4.7	62

#	Article	IF	CITATIONS
55	The Antiviral Efficacy of HIV-Specific CD8+ T-Cells to a Conserved Epitope Is Heavily Dependent on the Infecting HIV-1 Isolate. PLoS Pathogens, 2011, 7, e1001341.	4.7	26
56	Relationship between Functional Profile of HIV-1 Specific CD8 T Cells and Epitope Variability with the Selection of Escape Mutants in Acute HIV-1 Infection. PLoS Pathogens, 2011, 7, e1001273.	4.7	90
57	The immune response during acute HIV-1 infection: clues for vaccine development. Nature Reviews Immunology, 2010, 10, 11-23.	22.7	707
58	Elevation of Intact and Proteolytic Fragments of Acute Phase Proteins Constitutes the Earliest Systemic Antiviral Response in HIV-1 Infection. PLoS Pathogens, 2010, 6, e1000893.	4.7	80
59	First-Class Control of HIV-1. Science, 2010, 330, 1488-1490.	12.6	27
60	Transmission of Single HIV-1 Genomes and Dynamics of Early Immune Escape Revealed by Ultra-Deep Sequencing. PLoS ONE, 2010, 5, e12303.	2.5	259
61	New templates for HIV-1 antibody-based vaccine design. F1000 Biology Reports, 2010, 2, 60.	4.0	20
62	The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. Journal of Experimental Medicine, 2009, 206, 1253-1272.	8.5	562
63	Common Genetic Variation and the Control of HIV-1 in Humans. PLoS Genetics, 2009, 5, e1000791.	3.5	377
64	Increased detection of proliferating, polyfunctional, HIVâ€1â€specific T cells in DNAâ€modified vaccinia virus Ankaraâ€vaccinated human volunteers by cultured IFNâ€Î³ ELISPOT assay. European Journal of Immunology, 2009, 39, 975-985.	2.9	23
65	Novel HIVâ€1 clade B candidate vaccines designed for HLAâ€B [*] 5101 ⁺ patients protected mice against chimaeric ecotropic HIVâ€1 challenge. European Journal of Immunology, 2009, 39, 1831-1840.	2.9	22
66	Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance. Nature Immunology, 2009, 10, 636-646.	14.5	170
67	Lessons from IAVI-006, a Phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. Vaccine, 2008, 26, 6671-6677.	3.8	50
68	Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. Journal of Clinical Investigation, 2008, 118, 3478-90.	8.2	373
69	Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. Journal of General Virology, 2007, 88, 1-12.	2.9	118
70	AIDS/HIV: Finding Footprints Among the Trees. Science, 2007, 315, 1505-1507.	12.6	12
71	Escape from the Dominant HLA-B27-Restricted Cytotoxic T-Lymphocyte Response in Gag Is Associated with a Dramatic Reduction in Human Immunodeficiency Virus Type 1 Replication. Journal of Virology, 2007, 81, 12382-12393.	3.4	299
72	Triple bypass: complicated paths to HIV escape. Journal of Experimental Medicine, 2007, 204, 2785-2788.	8.5	15

#	Article	IF	CITATIONS
73	A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1. Science, 2007, 317, 944-947.	12.6	1,136
74	Design and Pre-Clinical Evaluation of a Universal HIV-1 Vaccine. PLoS ONE, 2007, 2, e984.	2.5	247
75	From influenza to HIV—and back?. Nature Immunology, 2007, 8, 1149-1151.	14.5	3
76	HIV VACCINES. Annual Review of Immunology, 2006, 24, 227-255.	21.8	257
77	Conflicting selective forces affect T cell receptor contacts in an immunodominant human immunodeficiency virus epitope. Nature Immunology, 2006, 7, 179-189.	14.5	91
78	Induction of long-lasting multi-specific CD8+T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques. European Journal of Immunology, 2006, 36, 2574-2584.	2.9	24
79	Induction of Multifunctional Human Immunodeficiency Virus Type 1 (HIV-1)-Specific T Cells Capable of Proliferation in Healthy Subjects by Using a Prime-Boost Regimen of DNA- and Modified Vaccinia Virus Ankara-Vectored Vaccines Expressing HIV-1 Gag Coupled to CD8 + T-Cell Epitopes. Journal of Virology, 2006. 80. 4717-4728.	3.4	220
80	Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-B*2705. European Journal of Immunology, 2005, 35, 341-351.	2.9	99
81	A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. Journal of General Virology, 2004, 85, 911-919.	2.9	206
82	T Cell Cross-Reactivity and Conformational Changes during TCR Engagement. Journal of Experimental Medicine, 2004, 200, 1455-1466.	8.5	159
83	HIV-specific Cytotoxic T Cells from Long-Term Survivors Select a Unique T Cell Receptor. Journal of Experimental Medicine, 2004, 200, 1547-1557.	8.5	103
84	Ex Vivo Phenotype and Frequency of Influenza Virus-Specific CD4 Memory T Cells. Journal of Virology, 2004, 78, 7284-7287.	3.4	67
85	A review of vaccines for HIV prevention. Journal of Gene Medicine, 2003, 5, 3-10.	2.8	24
86	A structural basis for immunodominant human T cell receptor recognition. Nature Immunology, 2003, 4, 657-663.	14.5	290
87	HIV vaccines 1983–2003. Nature Medicine, 2003, 9, 874-880.	30.7	240
88	MEDICINE: Enhanced: The Need for a Global HIV Vaccine Enterprise. Science, 2003, 300, 2036-2039.	12.6	186
89	Characterization of the CD4+ T Cell Response to Epstein-Barr Virus during Primary and Persistent Infection. Journal of Experimental Medicine, 2003, 198, 903-911.	8.5	199
90	Requirement of the Proteasome for the Trimming of Signal Peptide-derived Epitopes Presented by the Nonclassical Major Histocompatibility Complex Class I Molecule HLA-E. Journal of Biological Chemistry, 2003, 278, 33747-33752.	3.4	54

#	Article	IF	CITATIONS
91	HIV/AIDS: HLA Leaves Its Footprints on HIV. Science, 2002, 296, 1410-1411.	12.6	62
92	Identification and Characterisation of Derp1-Specific CD8+ T Cells in the Peripheral Blood of Atopic Individuals. Clinical Science, 2002, 103, 2P-2P.	0.0	0
93	The use of tetramers in the quantitative analysis of T-cell responses. Methods in Microbiology, 2002, , 125-156.	0.8	0
94	Design and Validation of an Enzyme-Linked Immunospot Assay for Use in Clinical Trials of Candidate HIV Vaccines. AIDS Research and Human Retroviruses, 2002, 18, 611-618.	1.1	70
95	Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nature Medicine, 2002, 8, 379-385.	30.7	1,432
96	A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques. Journal of General Virology, 2002, 83, 75-80.	2.9	72
97	Epitope specificity of clonally expanded populations of CD8+ T cells found within the joints of patients with inflammatory arthritis. Arthritis and Rheumatism, 2001, 44, 2038-2045.	6.7	40
98	Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature, 2001, 410, 106-111.	27.8	910
99	Cellular immune responses to HIV. Nature, 2001, 410, 980-987.	27.8	550
100	Clustered Mutations in HIV-1 Gag Are Consistently Required for Escape from Hla-B27–Restricted Cytotoxic T Lymphocyte Responses. Journal of Experimental Medicine, 2001, 193, 375-386.	8.5	424
101	Cytotoxic T–cell abundance and virus load in human immunodeficiency virus type 1 and human T–cell leukaemia virus type 1. Proceedings of the Royal Society B: Biological Sciences, 2001, 268, 1215-1221.	2.6	54
102	Effects of Retroviral Protease Inhibitors on Proteasome Function and Processing of HIV-Derived MHC Class I-Restricted Cytotoxic T Lymphocyte Epitopes. AIDS Research and Human Retroviruses, 2001, 17, 1063-1066.	1.1	12
103	Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. Journal of Clinical Investigation, 2001, 107, 341-349.	8.2	190
104	Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection. Aids, 2000, 14, 225-233.	2.2	140
105	HLA-E is expressed on trophoblast and interacts with CD94 / NKG2 receptors on decidual NK cells. European Journal of Immunology, 2000, 30, 1623-1631.	2.9	379
106	Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya Nature Medicine, 2000, 6, 951-955.	30.7	190
107	Induction of AIDS Virus-Specific CTL Activity in Fresh, Unstimulated Peripheral Blood Lymphocytes from Rhesus Macaques Vaccinated with a DNA Prime/Modified Vaccinia Virus Ankara Boost Regimen. Journal of Immunology, 2000, 164, 4968-4978.	0.8	247
108	HIV-Specific Cd8+ T Cells Produce Antiviral Cytokines but Are Impaired in Cytolytic Function. Journal of Experimental Medicine, 2000, 192, 63-76.	8.5	820

#	Article	IF	CITATIONS
109	HIV-1-Specific Mucosal CD8+ Lymphocyte Responses in the Cervix of HIV-1-Resistant Prostitutes in Nairobi. Journal of Immunology, 2000, 164, 1602-1611.	0.8	361
110	Surface Expression of HLA-E, an Inhibitor of Natural Killer Cells, Enhanced by Human Cytomegalovirus gpUL40. Science, 2000, 287, 1031-1033.	12.6	554
111	The dynamics of the cellular immune response to HIV infection: implications for vaccination. Philosophical Transactions of the Royal Society B: Biological Sciences, 2000, 355, 1007-1011.	4.0	24
112	Induction of Fas Ligand Expression by HIV Involves the Interaction of Nef with the T Cell Receptor ζ Chain. Journal of Experimental Medicine, 1999, 189, 1489-1496.	8.5	231
113	Functions of nonclassical MHC and non-MHC-encoded class I molecules. Current Opinion in Immunology, 1999, 11, 100-108.	5.5	207
114	Pre-clinical development of a multi-CTL epitope-based DNA prime MVA boost vaccine for AIDS. Immunology Letters, 1999, 66, 177-181.	2.5	88
115	T cell receptor usage in infectious disease. Seminars in Immunopathology, 1999, 21, 37-54.	4.0	10
116	Is an HIV vaccine possible?. Nature Medicine, 1999, 5, 612-614.	30.7	34
117	The role of HLA-B27 in spondyloarthritis. Immunogenetics, 1999, 50, 220-227.	2.4	78
118	BirA Enzyme: Production and Application in the Study of Membrane Receptor–Ligand Interactions by Site-Specific Biotinylation. Analytical Biochemistry, 1999, 266, 9-15.	2.4	104
119	Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime. Vaccine, 1999, 17, 589-596.	3.8	97
120	T cell receptor usage in infectious disease. Seminars in Immunopathology, 1999, 21, 37-54.	4.0	2
121	Effective Induction of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Macaques by Using a Multiepitope Gene and DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccination Regimen. Journal of Virology, 1999, 73, 7524-7532.	3.4	288
122	The arrival of HLA class II tetramers. Journal of Clinical Investigation, 1999, 104, 1669-1670.	8.2	29
123	Rapid Death of Adoptively Transferred T Cells in Acquired Immunodeficiency Syndrome. Blood, 1999, 93, 1506-1510.	1.4	104
124	Rapid Death of Adoptively Transferred T Cells in Acquired Immunodeficiency Syndrome. Blood, 1999, 93, 1506-1510.	1.4	16
125	The original sin of killer T cells. Nature, 1998, 394, 421-422.	27.8	34
126	HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature, 1998, 391, 795-799.	27.8	1,983

#	Article	IF	CITATIONS
127	TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide. Current Biology, 1998, 8, 1-10.	3.9	258
128	Differential processing of influenza nucleoprotein in human and mouse cells. European Journal of Immunology, 1998, 28, 625-635.	2.9	25
129	Evidence for the persistence of monoclonal expansions of CD8+ T cells following primary simian immunodeficiency virus infection. European Journal of Immunology, 1998, 28, 1172-1180.	2.9	22
130	Importance of a conserved TCR J α-encoded tyrosine for T cell recognition of an HLA B27/ peptide complex. European Journal of Immunology, 1998, 28, 2704-2713.	2.9	18
131	Production, crystallization, and preliminary Xâ€ray analysis of the human MHC class Ib molecule HLAâ€E. Protein Science, 1998, 7, 1264-1266.	7.6	32
132	Structural Features Impose Tight Peptide Binding Specificity in the Nonclassical MHC Molecule HLA-E. Molecular Cell, 1998, 1, 531-541.	9.7	190
133	T Cell Responses and Viral Escape. Cell, 1998, 93, 673-676.	28.9	127
134	Quantitation of HIV-1-Specific Cytotoxic T Lymphocytes and Plasma Load of Viral RNA. Science, 1998, 279, 2103-2106.	12.6	1,340
135	Oligoclonal Expansions of CD8+ T Cells in Chronic HIV Infection Are Antigen Specific. Journal of Experimental Medicine, 1998, 188, 785-790.	8.5	153
136	Mechanisms of Protection Induced by Attenuated Simian Immunodeficiency Virus II. Lymphocyte Depletion Does Not Abrogate Protection. AIDS Research and Human Retroviruses, 1998, 14, 1187-1198.	1.1	38
137	A New Look at T Cells. Journal of Experimental Medicine, 1998, 187, 1367-1371.	8.5	265
138	Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice Journal of General Virology, 1998, 79, 83-90.	2.9	79
139	Evasion of Cytotoxic T Lymphocyte (CTL) Responses by Nef-dependent Induction of Fas Ligand (CD95L) Expression on Simian Immunodeficiency Virus–infected Cells. Journal of Experimental Medicine, 1997, 186, 7-16.	8.5	199
140	Rapid Effector Function in CD8+ Memory T Cells. Journal of Experimental Medicine, 1997, 186, 859-865.	8.5	626
141	ESCAPE OF HUMAN IMMUNODEFICIENCY VIRUS FROM IMMUNE CONTROL. Annual Review of Immunology, 1997, 15, 271-296.	21.8	315
142	How viruses hide from T cells. Trends in Microbiology, 1997, 5, 211-212.	7.7	5
143	Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nature Medicine, 1997, 3, 212-217.	30.7	1,096
144	Crystal structure of the complex between human CD8 \hat{i} ± \hat{i} ± and HLA-A2. Nature, 1997, 387, 630-634.	27.8	428

#	Article	IF	CITATIONS
145	Engagement of a T cell receptor by major histocompatibility complex irrespective of peptide. European Journal of Immunology, 1997, 27, 879-885.	2.9	7
146	The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. European Journal of Immunology, 1997, 27, 1164-1169.	2.9	442
147	Combined structural and immunological refinement of HIV-1 HLA-B8-restricted cytotoxic T lymphocyte epitopes. European Journal of Immunology, 1997, 27, 1515-1521.	2.9	30
148	Production and crystallization of MHC class I B allele single peptide complexes. FEBS Letters, 1996, 383, 119-123.	2.8	33
149	Introduction: Presentation of viral antigens to cytotoxic T cells. Seminars in Virology, 1996, 7, 1-2.	3.9	4
150	Bound Water Structure and Polymorphic Amino Acids Act Together to Allow the Binding of Different Peptides to MHC Class I HLA-B53. Immunity, 1996, 4, 215-228.	14.3	155
151	Homocysteine modification of HLA antigens and its immunological consequences. European Journal of Immunology, 1996, 26, 1443-1450.	2.9	39
152	Large clonal expansions of CD8+ T cells in acute infectious mononucleosis. Nature Medicine, 1996, 2, 906-911.	30.7	469
153	Antagonist HIV-1 Gag Peptides Induce Structural Changes in HLA B8. Journal of Experimental Medicine, 1996, 184, 2279-2286.	8.5	136
154	Immune Escape in Hiv Infection. Clinical Science, 1995, 88, 31P-31P.	0.0	0
155	Selection of T cell receptor variable gene-encoded amino acids on the third binding site loop: a factor influencing variable chain selection in a T cell response. European Journal of Immunology, 1995, 25, 1529-1534.	2.9	17
156	The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus. European Journal of Immunology, 1995, 25, 1927-1931.	2.9	75
157	Peptide anchor residue glycosylation: effect on class I major histocompatibility complex binding and cytotoxic T lymphocyte recognition. European Journal of Immunology, 1995, 25, 3270-3276.	2.9	74
158	Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature, 1995, 375, 606-611.	27.8	342
159	Immune responses in HIV-exposed seronegatives: have they repelled the virus?. Current Opinion in Immunology, 1995, 7, 448-455.	5.5	183
160	Recognition of viral antigens at the cell surface. Cancer Surveys, 1995, 22, 51-62.	1.5	2
161	Identification of T cell receptor recognition residues for a viral peptide presented by HLA B27. European Journal of Immunology, 1994, 24, 2357-2363.	2.9	49
162	Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature, 1994, 369, 403-407.	27.8	438

#	Article	IF	CITATIONS
163	Cytotoxic T Lymphocytes Specific for Influenza Virus. Current Topics in Microbiology and Immunology, 1994, 189, 75-91.	1.1	53
164	Expression and function of HLA-B27 in lipid-linked form: Implications for cytotoxic T lymphocyte-induced apoptosis signal transduction. European Journal of Immunology, 1993, 23, 653-658.	2.9	12
165	An antigen processing polymorphism revealed by HLA-B8-restricted cytotoxic T lymphocytes which does not correlate with TAP gene polymorphism. European Journal of Immunology, 1993, 23, 1999-2004.	2.9	32
166	Peptide selection by class I molecules of the major histocompatibility complex. Current Biology, 1993, 3, 854-866.	3.9	71
167	Natural selection at work on the surface of virus-infected cells. Science, 1993, 260, 1771-1772.	12.6	14
168	Cytotoxic T Lymphocytes: Specificity, Surveillance, and Escape. Advances in Cancer Research, 1992, 59, 227-244.	5.0	10
169	Role of class I molecules of the major histocompatibility complex in cytotoxic T-cell function in health and disease. Seminars in Immunopathology, 1992, 14, 1-16.	4.0	9
170	Maintenance of MHC polymorphism. Nature, 1992, 355, 403-403.	27.8	15
171	Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature, 1992, 360, 434-439.	27.8	638
172	A cross-species functional interaction between the murine major histocompatibility complex class I α3 domain and human CD8 revealed by peptide-specific cytotoxic T lymphocytes. European Journal of Immunology, 1992, 22, 1643-1646.	2.9	13
173	Cytotoxic T lymphocytes and immune surveillance. Cancer Surveys, 1992, 13, 5-21.	1.5	9
174	HLA B27: a disease-associated immune response gene. Research in Immunology, 1991, 142, 475-482.	0.9	8
175	Common West African HLA antigens are associated with protection from severe malaria. Nature, 1991, 352, 595-600.	27.8	1,494
176	Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature, 1991, 354, 453-459.	27.8	1,060
177	Nosing ahead in the cold war. Nature, 1990, 344, 16-16.	27.8	7
178	Presentation of viral antigen controlled by a gene in the major histocompatibility complex. Nature, 1990, 345, 449-452.	27.8	379
179	Tamarin compatibility. Nature, 1990, 346, 17-17.	27.8	2
180	Why the long latent period?. Nature, 1990, 348, 388-388.	27.8	10

#	Article	IF	CITATIONS
181	Class I cross-restricted T cells reveal low responder allele due to processing of viral antigen. Nature, 1989, 337, 653-655.	27.8	52
182	HIV-1 gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature, 1988, 336, 484-487.	27.8	471
183	Cytotoxic T lymphocytes recognize a fragment of influenza virus matrix protein in association with HLA-A2. Nature, 1987, 326, 881-882.	27.8	420
184	Simplification of twoâ€dimensional gel patterns of HLA class II antigens. Tissue Antigens, 1986, 28, 72-83.	1.0	1
185	Characterization of the HLA-A2.2 subtype: T cell evidence for further heterogeneity. Immunogenetics, 1985, 21, 11-23.	2.4	38
186	Effects of monoclonal antibodies to the a and β chains of the human lymphocyte function-associated (H-LFA-1) antigen on T lymphocyte functions. European Journal of Immunology, 1985, 15, 888-892.	2.9	54
187	A human lymphocyte-associated antigen involved in cell-mediated lympholysis. European Journal of Immunology, 1983, 13, 202-208.	2.9	315
188	Cytotoxic T-Cell Immunity to Influenza. New England Journal of Medicine, 1983, 309, 13-17.	27.0	918
189	Lysis of allogeneic human lymphocytes by nonspecifically activated T-like cells. European Journal of Immunology, 1982, 12, 1002-1005.	2.9	17
190	Effects Of A Monoclonal Antibody To Human Platelet Glycoprotein I On Platelet - Von Willebrand Factor Subendothelium Interactions. Thrombosis and Haemostasis, 1981, 46, 0297.	3.4	0
191	Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. II. Blocking studies with monoclonal antibodies to HLA determinants. European Journal of Immunology, 1981, 11, 694-699.	2.9	63